The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen
Open accessAbstract
We describe herein a protocol for the production of antigen-specific human monoclonal antibodies (hmAbs). Antibody-secreting cells (ASCs) are isolated from whole blood collected 7 d after vaccination and sorted by flow cytometry into single cell plates. The antibody genes of the ASCs are then amplified by RT-PCR and nested PCR, cloned into expression vectors and transfected into a human cell line. The expressed antibodies can then be purified and assayed for binding and neutralization. This method uses established techniques but is novel in their combination and application. This protocol can be completed with as little as 20 ml of human blood and in as little as 28 d when optimal. Although previous methodologies to produce hmAbs, including B-cell immortalization or phage display, can be used to isolate the rare specific antibody even years after immunization, in comparison, these approaches are inefficient, resulting in few relevant antibodies. Although dependent on having an ongoing immune response, the approach described herein can be used to rapidly generate numerous antigen-specific hmAbs in a short time.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Boussif, O., Lezoualc'h, F., Zanta, M. A., Mergny, M. D., Scherman, D., Demeneix, B., & Behr, J. P. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.16.7297 · Cited by 6,247
Characteristics of a human cell line transformed by DNA from human adenovirus type 5
Graham, F. L., Russell, W. C., Smiley, J., & Nairn, R. (1977) · Journal of General Virology · doi:10.1099/0022-1317-36-1-59 · Cited by 4,793
Phage antibodies: filamentous phage displaying antibody variable domains
McCafferty, J., Griffiths, A. D., Winter, G., & Chiswell, D. J. (1990) · Nature · doi:10.1038/348552a0 · Cited by 2,423
Predominant Autoantibody Production by Early Human B Cell Precursors
Wardemann, H., Yurasov, S., Schaefer, A., Young, J. W., Meffre, E., & Nussenzweig, M. C. (2003) · Science · doi:10.1126/science.1086907 · Cited by 2,083
Epidemiology and Prevention of Vaccine-Preventable Diseases
Atkinson, W. W. (2009) · Cited by 1,862
Replacing the complementarity-determining regions in a human antibody with those from a mouse
Jones, P. T., Dear, P. H., Foote, J., Neuberger, M. S., & Winter, G. (1986) · Nature · doi:10.1038/321522a0 · Cited by 1,406
Tiller, T., Meffre, E., Yurasov, S., Tsuiji, M., Nussenzweig, M. C., & Wardemann, H. (2008) · Journal of Immunological Methods · doi:10.1016/j.jim.2007.09.017 · Cited by 1,107
Rapid cloning of high-affinity human monoclonal antibodies against influenza virus
Wrammert, J., Smith, K., Miller, J., Langley, W. A., Kokko, K., Larsen, C., Zheng, N.-Y., Mays, I., Garman, L., Helms, C., et al. (2008) · Nature · doi:10.1038/nature06890 · Cited by 1,025
Self-citationNeutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors
Yu, X., Tsibane, T., McGraw, P. A., House, F. S., Keefer, C. J., Hicar, M. D., Tumpey, T. M., Pappas, C., Perrone, L. A., Martinez, O., et al. (2008) · Nature · doi:10.1038/nature07231 · Cited by 452
Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system
Crotty, S., Aubert, R. D., Glidewell, J., & Ahmed, R. (2004) · Journal of Immunological Methods · doi:10.1016/j.jim.2003.12.015 · Cited by 421
Self-citation
Cited by
Development of therapeutic antibodies for the treatment of diseases
Lu, R.-M., Hwang, Y.-C., Liu, I.-J., Lee, C.-C., Tsai, H.-Z., Li, H.-J., & Wu, H.-C. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0592-z · Cited by 2,085
A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
Chi, X., Yan, R., Zhang, J., Zhang, G., Zhang, Y., Hao, M., Zhang, Z., Fan, P., Dong, Y., Yang, Y., et al. (2020) · Science · doi:10.1126/science.abc6952 · Cited by 1,385
SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses
Turner, J. S., O’Halloran, J. A., Kalaidina, E., Kim, W., Schmitz, A. J., Zhou, J. Q., Lei, T., Thapa, M., Chen, R. E., Case, J. B., et al. (2021) · Nature · doi:10.1038/s41586-021-03738-2 · Cited by 831
Wrammert, J., Koutsonanos, D., Li, G.-M., Edupuganti, S., Sui, J., Morrissey, M., McCausland, M., Skountzou, I., Hornig, M., Lipkin, W. I., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101352 · Cited by 777
Self-citationFunctional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19
Rodda, L. B., Netland, J., Shehata, L., Pruner, K. B., Morawski, P. A., Thouvenel, C. D., Takehara, K. K., Eggenberger, J., Hemann, E. A., Waterman, H. R., et al. (2021) · Cell · doi:10.1016/j.cell.2020.11.029 · Cited by 647
Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients
Suthar, M. S., Zimmerman, M. G., Kauffman, R. C., Mantus, G., Linderman, S. L., Hudson, W. H., Vanderheiden, A., Nyhoff, L., Davis, C. W., Adekunle, O., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100040 · Cited by 508
Self-citationDejnirattisai, W., Wongwiwat, W., Supasa, S., Zhang, X., Dai, X., Rouvinski, A., Jumnainsong, A., Edwards, C., Quyen, N. T. H., Duangchinda, T., et al. (2015) · Nature Immunology · doi:10.1038/ni.3058 · Cited by 500
Natural polyreactive IgA antibodies coat the intestinal microbiota
Bunker, J. J., Erickson, S. A., Flynn, T. M., Henry, C., Koval, J. C., Meisel, M., Jabri, B., Antonopoulos, D. A., Wilson, P. C., & Bendelac, A. (2017) · Science · doi:10.1126/science.aan6619 · Cited by 468
Self-citationHigh-throughput sequencing of the paired human immunoglobulin heavy and light chain repertoire
DeKosky, B. J., Ippolito, G. C., Deschner, R. P., Lavinder, J. J., Wine, Y., Rawlings, B. M., Varadarajan, N., Giesecke, C., Dörner, T., Andrews, S. F., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2492 · Cited by 410
Self-citationBonsignori, M., Hwang, K.-K., Chen, X., Tsao, C.-Y., Morris, L., Gray, E., Marshall, D. J., Crump, J. A., Kapiga, S. H., Sam, N. E., et al. (2011) · Journal of Virology · doi:10.1128/jvi.05045-11 · Cited by 423
Chen, Y.-Q., Wohlbold, T. J., Zheng, N.-Y., Huang, M., Huang, Y., Neu, K. E., Lee, J., Wan, H., Rojas, K. T., Kirkpatrick, E., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.030 · Cited by 416
Self-citationImmune history profoundly affects broadly protective B cell responses to influenza
Andrews, S. F., Huang, Y., Kaur, K., Popova, L. I., Ho, I. Y., Pauli, N. T., Dunand, C. J. H., Taylor, W. M., Lim, S., Huang, M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aad0522 · Cited by 411
Self-citationNew insights into the immunopathology and control of dengue virus infection
Screaton, G., Mongkolsapaya, J., Yacoub, S., & Roberts, C. (2015) · Nature Reviews Immunology · doi:10.1038/nri3916 · Cited by 394
Li, G.-M., Chiu, C., Wrammert, J., McCausland, M., Andrews, S. F., Zheng, N.-Y., Lee, J.-H., Huang, M., Qu, X., Edupuganti, S., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1118979109 · Cited by 393
Self-citationIn-depth determination and analysis of the human paired heavy- and light-chain antibody repertoire
DeKosky, B. J., Kojima, T., Rodin, A., Charab, W., Ippolito, G. C., Ellington, A. D., & Georgiou, G. (2015) · Nature Medicine · doi:10.1038/nm.3743 · Cited by 357
Therapies for rare diseases: therapeutic modalities, progress and challenges ahead
Tambuyzer, E., Vandendriessche, B., Austin, C. P., Brooks, P. J., Larsson, K., Miller Needleman, K. I., Valentine, J., Davies, K., Groft, S. C., Preti, R., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0049-9 · Cited by 357
James, L. K., Shamji, M. H., Walker, S. M., Wilson, D. R., Wachholz, P. A., Francis, J. N., Jacobson, M. R., Kimber, I., Till, S. J., & Durham, S. R. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.12.1080 · Cited by 342
Human germinal centres engage memory and naive B cells after influenza vaccination
Turner, J. S., Zhou, J. Q., Han, J., Schmitz, A. J., Rizk, A. A., Alsoussi, W. B., Lei, T., Amor, M., McIntire, K. M., Meade, P., et al. (2020) · Nature · doi:10.1038/s41586-020-2711-0 · Cited by 304
Chen, X., Li, R., Pan, Z., Qian, C., Yang, Y., You, R., Zhao, J., Liu, P., Gao, L., Li, Z., et al. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0426-7 · Cited by 332
Sasaki, S., Sullivan, M., Narvaez, C. F., Holmes, T. H., Furman, D., Zheng, N.-Y., Nishtala, M., Wrammert, J., Smith, K., James, J. A., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57834 · Cited by 300
Self-citationHigh frequency of shared clonotypes in human B cell receptor repertoires
Soto, C., Bombardi, R. G., Branchizio, A., Kose, N., Matta, P., Sevy, A. M., Sinkovits, R. S., Gilchuk, P., Finn, J. A., & Crowe, J. E. (2019) · Nature · doi:10.1038/s41586-019-0934-8 · Cited by 294
SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2
Amanat, F., Thapa, M., Lei, T., Ahmed, S. M. S., Adelsberg, D. C., Carreño, J. M., Strohmeier, S., Schmitz, A. J., Zafar, S., Zhou, J. Q., et al. (2021) · Cell · doi:10.1016/j.cell.2021.06.005 · Cited by 273
Targeting the Tumor Microenvironment with Interferon-β Bridges Innate and Adaptive Immune Responses
Yang, X., Zhang, X., Fu, M. L., Weichselbaum, R. R., Gajewski, T. F., Guo, Y., & Fu, Y.-X. (2014) · Cancer Cell · doi:10.1016/j.ccr.2013.12.004 · Cited by 269
Lau, D., Lan, L. Y.-L., Andrews, S. F., Henry, C., Rojas, K. T., Neu, K. E., Huang, M., Huang, Y., DeKosky, B., Palm, A.-K. E., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aai8153 · Cited by 269
Self-citationHenry Dunand, C. J., Leon, P. E., Huang, M., Choi, A., Chromikova, V., Ho, I. Y., Tan, G. S., Cruz, J., Hirsh, A., Zheng, N.-Y., et al. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.05.014 · Cited by 268
Self-citationBroadly protective human antibodies that target the active site of influenza virus neuraminidase
Stadlbauer, D., Zhu, X., McMahon, M., Turner, J. S., Wohlbold, T. J., Schmitz, A. J., Strohmeier, S., Yu, W., Nachbagauer, R., Mudd, P. A., et al. (2019) · Science · doi:10.1126/science.aay0678 · Cited by 260
Saphire, E. O., Schendel, S. L., Fusco, M. L., Gangavarapu, K., Gunn, B. M., Wec, A. Z., Halfmann, P. J., Brannan, J. M., Herbert, A. S., Qiu, X., et al. (2018) · Cell · doi:10.1016/j.cell.2018.07.033 · Cited by 212
Self-citationTargeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer
Su, Y., Liu, Y., Behrens, C. R., Bidlingmaier, S., Lee, N.-K., Aggarwal, R., Sherbenou, D. W., Burlingame, A. L., Hann, B. C., Simko, J. P., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.121497 · Cited by 82
A public vaccine-induced human antibody protects against SARS-CoV-2 and emerging variants
Schmitz, A. J., Turner, J. S., Liu, Z., Aziati, I. D., Chen, R. E., Joshi, A., Bricker, T. L., Darling, T. L., Adelsberg, D. C., Alsoussi, W. B., et al. (2021) · doi:10.1101/2021.03.24.436864 · Cited by 72
Ojima-Kato, T., Nagai, S., & Nakano, H. (2017) · Scientific Reports · doi:10.1038/s41598-017-14277-0 · Cited by 44
Ojima-Kato, T., Hashimura, D., Kojima, T., Minabe, S., & Nakano, H. (2015) · Journal of Immunological Methods · doi:10.1016/j.jim.2015.10.001 · Cited by 31
de Mattos Barbosa, M. G., Liu, H., Huynh, D., Shelley, G., Keller, E. T., Emmer, B. T., Sherman, E., Ginsburg, D., Kennedy, A. A., Tai, A. W., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.147386 · Cited by 14
Molecular basis of SARS-CoV-2 Omicron variant evasion from shared neutralizing antibody response
(2023) · doi:10.1016/j.str.2023.04.010 · Cited by 11
Hastie, K. M., Salie, Z. L., Ke, Z., Halfmann, P. J., DeWald, L. E., McArdle, S., Grinyó, A., Davidson, E., Schendel, S. L., Hariharan, C., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56452-2 · Cited by 9
Self-citation
Metadata
- Authors
- Smith, K., Garman, L., Wrammert, J., Zheng, N.-Y., Capra, J. D., Ahmed, R., & Wilson, P. C.
- Venue
- Nature Protocols
- Published
- 2009-02-26
- Volume
- 4
- Issue
- 3
- Pages
- 372-384
- ISSN
- 1750-2799 (ISSN-L)
- 1754-2189
- OpenAlex
- W1996626942
- Cited by
- 470
- References
- 19
- FWCI
- 12.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.